Acute Respiratory Distress Syndrome

Acute Respiratory Distress Syndrome (ARDS) is a life-threatening form of acute hypoxemic respiratory failure characterized by bilateral pulmonary infiltrates and severe hypoxemia without cardiogenic pulmonary edema, resulting from increased alveolar-capillary permeability. First described in 1967, ARDS remains a major cause of morbidity and mortality in intensive care units, affecting approximately 190,000 patients annually in the United States with mortality rates of 30-40%. The syndrome occurs across all age groups but carries higher mortality in elderly patients and those with underlying comorbidities such as cirrhosis or immunosuppression. ARDS represents the pulmonary manifestation of systemic inflammation and is essential to recognize and manage appropriately, as it appears frequently on board examinations and in clinical practice. The condition's variable presentation and heterogeneous underlying causes make it a challenging diagnosis requiring systematic clinical assessment. Understanding ARDS pathophysiology, diagnostic criteria, and evidence-based management protocols is critical for Step 2 CK success and optimal patient outcomes.

ARDS develops through a biphasic inflammatory cascade initiated by either direct pulmonary injury (primary/direct ARDS) or systemic inflammation with secondary lung involvement (secondary/indirect ARDS). The fundamental pathophysiology centers on increased alveolar-capillary permeability leading to non-cardiogenic pulmonary edema, severe hypoxemia, and progressive respiratory failure.

The initiating event involves direct or indirect activation of alveolar epithelial cells and pulmonary microvascular endothelial cells. Damage-associated molecular patterns (DAMPs) released by necrotic cells and pathogen-associated molecular patterns (PAMPs) activate pattern recognition receptors (TLRs, NOD-like receptors), triggering nuclear factor-kappa B (NF-κB) activation. This transcription factor upregulates production of pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-α), interleukin-1β (IL-1β), and interleukin-8 (IL-8). The resulting inflammatory cascade increases tight junction permeability at both epithelial (occludin, claudins, ZO-1 disruption) and endothelial levels, allowing fluid transudation into the alveolar space. Surfactant protein A and D (opsonins) are depleted, reducing innate immune function. The Type I pneumocyte layer, covering 95% of alveolar surface area and normally impermeable, becomes focally denuded, exposing the basement membrane. This epithelial injury is initially reversible but progresses to permanent damage with Type I pneumocyte apoptosis, loss of epithelial integrity, and protein-rich fluid accumulation.

Neutrophil-mediated injury represents the pathologic hallmark of ARDS. Endothelial expression of adhesion molecules (E-selectin, P-selectin, ICAM-1, VCAM-1) is upregulated by TNF-α, IL-1β, and IL-6. Chemokines CXCL8 (IL-8) and CXCL2 create a gradient attracting circulating neutrophils through a four-step process: rolling (selectin-mediated), firm adhesion (integrin-mediated), transmigration, and activation. Recruited neutrophils release proteolytic enzymes (neutrophil elastase, collagenase, gelatinase), reactive oxygen species (superoxide anion, hydroxyl radical, hypochlorous acid), and additional pro-inflammatory mediators (TNF-α, IL-1β, IL-8, leukotriene B4, platelet-activating factor). These mediators further amplify the inflammatory cascade in a positive feedback loop. Neutrophil extracellular traps (NETs) form through NETosis, trapping bacteria but also causing collateral tissue damage. The neutrophil influx into the alveolar space is dramatic, increasing from baseline ~10³ cells/mL to >10⁶ cells/mL, creating a dense inflammatory infiltrate that produces the characteristic alveolar consolidation on imaging.

The extrinsic coagulation pathway is activated by tissue factor (TF) expressed on activated monocytes and endothelial cells in response to inflammatory mediators. Thrombin generation overwhelms the endogenous anticoagulation system (protein C, protein S, antithrombin, tissue factor pathway inhibitor), leading to widespread microthrombosis within the pulmonary vasculature. Activation of protease-activated receptors (PARs) by thrombin on endothelial cells, platelets, and fibroblasts perpetuates inflammation. Fibrin-platelet microthrombi occlude capillaries, reducing functional alveolar units and contributing to ventilation-perfusion (V/Q) mismatch and hypoxemia. Impaired fibrinolysis occurs due to elevation of plasminogen activator inhibitor-1 (PAI-1), which inhibits tissue plasminogen activator (tPA). The balance between thrombin generation and fibrinolytic capacity determines the extent of microthrombosis.

The disrupted epithelial and endothelial barriers allow fluid transudation exceeding lymphatic drainage capacity, filling alveoli with protein-rich edema fluid (edema fluid-to-plasma protein ratio >0.7, diagnostic of increased permeability). Normally, active sodium transport via Na⁺/K⁺-ATPase pumps on the basolateral surface of Type II pneumocytes creates an osmotic gradient for fluid reabsorption. In ARDS, multiple mechanisms impair this clearance: (1) reduced Na⁺/K⁺-ATPase expression and activity secondary to oxidative stress, (2) mitochondrial dysfunction from reactive oxygen species and pro-inflammatory mediators, (3) apoptosis of epithelial cells, (4) impaired lymphatic drainage from elevated pulmonary hydrostatic pressure. The alveolar edema fluid accumulation is the direct cause of hypoxemia and increased work of breathing.

ARDS produces hypoxemia through multiple simultaneous mechanisms: (1) Intrapulmonary shunting from consolidated alveoli filled with edema fluid that are perfused but not ventilated (absolute shunt); (2) V/Q mismatch from areas with reduced ventilation relative to perfusion due to partial alveolar filling and airway closure; (3) Diffusion impairment from the thickened alveolar-capillary membrane due to interstitial and alveolar edema; (4) Reduced functional residual capacity (FRC) from alveolar collapse (atelectasis) during expiration due to loss of surfactant and small airway closure. The shunting component is refractory to supplemental oxygen, a characteristic feature of ARDS. Hypoxemia worsens in supine positions and improves with prone positioning due to redistribution of perfusion away from dependent consolidated regions and improved V/Q matching.

Surfactant protein synthesis decreases while clearance increases, leading to net depletion. Surfactant components that remain are inactivated by edema fluid proteins and oxidative modification. Surfactant dysfunction causes increased alveolar surface tension, predisposing to alveolar collapse during expiration and requiring higher pressures to re-expand alveoli (increased work of breathing). Loss of surfactant's immunomodulatory function (surfactant proteins A and D binding pattern recognition receptors) impairs innate immunity.

In the exudative phase (first 1-2 weeks), diffuse alveolar damage is characterized by epithelial cell necrosis, hyaline membrane formation, and neutrophil infiltration. If the inciting stimulus is controlled, a fibroproliferative phase begins (after 1-3 weeks), with proliferation of Type II pneumocytes attempting to re-epithelialize denuded areas, activation of alveolar macrophages and fibroblasts, and collagen deposition. Transforming growth factor-beta (TGF-β), basic fibroblast growth factor (bFGF), and connective tissue growth factor (CTGF) drive fibroblast proliferation and differentiation into myofibroblasts. In most survivors, this process resolves over weeks to months with restoration of normal lung architecture. However, in approximately 10-15% of survivors, progressive pulmonary fibrosis develops, resulting in permanent restrictive physiology and diffusion impairment. Increased TGF-β levels, persistent neutrophilic inflammation, mechanical ventilation parameters, and repeated episodes of hypoxemia are associated with progression to fibrosis.

The consolidated lung units in ARDS display markedly heterogeneous ventilation. Dependent lung regions are maximally compressed, leading to atelectasis and negligible ventilation despite continued perfusion (absolute shunt). Non-dependent regions remain relatively aerated but over-distend from preferential ventilation distribution. This spatial heterogeneity of ventilation explains why low positive end-expiratory pressure (PEEP) is associated with recurrent derecruitment and injury, while excessively high PEEP causes volutrauma.

ARDS results from a diverse array of pulmonary and systemic insults that activate the inflammatory cascade described above. Risk factors are stratified into direct lung injury (primary ARDS) and indirect systemic inflammation (secondary ARDS), with different etiologies carrying different prognoses.

Sepsis, particularly septic shock from bacterial, fungal, or viral infection, accounts for 40-50% of ARDS cases. Gram-negative organisms (Pseudomonas aeruginosa, Acinetobacter) and Gram-positive bacteria (Staphylococcus aureus, including MRSA) are most commonly implicated. Sepsis-induced ARDS typically presents as secondary ARDS with systemic inflammatory activation. Organ dysfunction scores and lactate elevation predict ARDS development. Delayed recognition and treatment of sepsis significantly increases ARDS risk.

Aspiration of gastric contents causes direct chemical pneumonitis and epithelial injury. Risk factors include altered consciousness (stroke, seizures, anesthesia), dysphagia (neurologic diseases, oropharyngeal pathology), and gastroesophageal reflux disease. Aspiration typically causes primary ARDS with acute onset within 2-24 hours. Gram-negative anaerobes from oral flora are frequently isolated.

Bacterial, viral (influenza, SARS-CoV-2, MERS-CoV, respiratory syncytial virus), fungal (Pneumocystis jirovecii in immunocompromised patients), and atypical (Mycoplasma, Chlamydia) pneumonias cause ARDS through either direct epithelial invasion or systemic cytokine release. Severe COVID-19 pneumonia has emerged as a major ARDS etiology, with unique features of endothelial dysfunction and thromboinflammation. Immunocompromised patients (HIV/AIDS, chemotherapy, transplant recipients) develop ARDS more frequently from opportunistic infections.

Blunt chest trauma, pulmonary contusion, rib fractures, and flail chest trigger inflammatory cascades leading to post-traumatic ARDS. Fat embolism syndrome from long bone fractures (femur, tibia) or orthopedic procedures causes ARDS through lipid-induced endothelial injury and activation of the coagulation cascade. Air embolism, though less common, causes acute severe ARDS. The timing of ARDS relative to trauma varies from immediate (direct injury) to delayed (hours to days from systemic inflammation).

Transfusion of blood products (packed red blood cells, fresh frozen plasma, platelets) can precipitate ARDS within 6 hours through two mechanisms: (1) HLA or granulocyte antibodies in donor blood binding to recipient leukocytes, causing activation and pulmonary sequestration, or (2) biogenic amines and lipid mediators in stored blood products directly activating endothelium. TRALI is a diagnosis of exclusion requiring temporal relationship to transfusion and absence of alternative explanations.

Severe acute pancreatitis triggers substantial inflammatory activation with release of pancreatic enzymes, activation of the complement cascade, and systemic cytokine release. ARDS develops in 5-10% of acute pancreatitis patients and is associated with increased mortality. The mechanism involves pancreatic enzyme-induced endothelial damage and neutrophil activation in the lungs.

Chemotherapy agents (bleomycin, methotrexate, gemcitabine) cause dose-dependent pulmonary toxicity culminating in ARDS. Antibiotics (nitrofurantoin), NSAIDs, acetylsalicylic acid, and antiretrovirals (zidovudine, abacavir) have been implicated. Heroin and cocaine use can precipitate acute pulmonary edema with ARDS features. Immunotherapy checkpoint inhibitors (anti-PD-1/PD-L1 agents) can cause immune-related pulmonary toxicity.

Massive transfusion protocols (>10 units packed RBCs) are independent risk factors for ARDS through multiple mechanisms: (1) stored blood products accumulation, (2) citrate toxicity and hypocalcemia, (3) dilutional coagulopathy, (4) systemic inflammation from transfused leukocytes and microparticles. Permissive hypotension strategies and balanced transfusion ratios (1:1:1 RBC:FFP:platelets) reduce ARDS incidence.

Direct pulmonary tissue trauma from blast injuries, near-drowning (freshwater aspiration causes surfactant washing), high-altitude pulmonary edema (HAPE), re-expansion pulmonary edema (rapid lung re-inflation after pneumothorax treatment or large pleural effusion drainage), and negative pressure pulmonary edema (hanging, severe airway obstruction) cause primary ARDS.

Ischemia-reperfusion injury during cardiac surgery, vascular surgery, or after cardiac arrest causes ARDS through reactive oxygen species generation upon reoxygenation. Intestinal ischemia with bacterial translocation and endotoxin absorption contributes to secondary ARDS.

Acute myocardial infarction with cardiogenic shock can progress to ARDS through splanchnic vasoconstriction, reduced organ perfusion, and activation of systemic inflammation. Distinguishing primary ARDS from cardiogenic pulmonary edema is crucial, as elevated pulmonary artery wedge pressure (PAWP >18 mmHg) argues against ARDS.

PCP in advanced AIDS patients (CD4 <50) classically presents with bilateral interstitial infiltrates and severe hypoxemia out of proportion to radiographic findings, often progressing to ARDS. Elevated LDH and serum-to-alveolar fluid LDH ratio >3 suggest PCP.

Smoke inhalation, chlorine gas exposure, phosgene, and other toxic inhalations cause chemical pneumonitis with acute ARDS development. Burned patients have extremely high ARDS incidence (up to 60%) from inhalation injury combined with systemic inflammation from thermal injury.

HIV/AIDS (CD4 <200), solid organ or hematopoietic stem cell transplantation, severe neutropenia, and iatrogenic immunosuppression (corticosteroids, calcineurin inhibitors, biologics) increase ARDS susceptibility through opportunistic infections and impaired immune regulation.

Chronic liver disease and cirrhosis increase ARDS risk through impaired immunity, increased bacterial translocation, and portal hypertension-induced endothelial dysfunction. Chronic kidney disease, diabetes mellitus, and malignancy are independent ARDS risk factors.

The clinical presentation of ARDS varies with the underlying etiology, rate of progression, and severity. Onset is typically acute, occurring within

ARDS is a clinical syndrome — there is no confirmatory blood test. Diagnosis rests on the Berlin Definition (2012), applied after the four elements below are documented.

Management is supportive: treat the precipitating cause (source control and empiric antimicrobials for sepsis, per Surviving Sepsis Campaign) while limiting ventilator-induced lung injury.